Tumor necrosis factor receptor-associated factor (TRAF) (TRAF)

Tumor necrosis factor receptor-associated factor (TRAF) proteins are a family of seven (TRAF1–7) intracellular scaffold proteins and E3 ubiquitin ligases that serve as critical hubs in signal transduction (UniProt, 2024). They primarily mediate signals from the TNF receptor (TNFR) superfamily, Toll-like receptors (TLRs), and Interleukin-1 receptors (IL-1Rs) to downstream pathways such as NF-kappaB, MAPK, and IRF (PubMed: 28273102). By regulating these pathways, TRAFs control essential biological processes including the innate and adaptive immune responses, cell survival, and bone metabolism (PubMed: 30108312). In disease contexts, overexpression or constitutive activation of TRAFs is associated with chronic inflammation, autoimmune diseases like rheumatoid arthritis, and various cancers where they drive tumor progression and therapeutic resistance (PubMed: 33458158). Although traditionally considered difficult to target, recent advances have led to the development of small molecules like C25-140 and peptide mimetics designed to disrupt TRAF-protein interactions or inhibit their RING domain-mediated ligase activity (PubMed: 29351476). These emerging therapies represent a novel approach to treating immune-mediated pathologies and hematological malignancies by precisely modulating intracellular signaling cascades.

Other names

TNF receptor-associated factorTRAF familyTRAF proteins

Inhibition of protein-protein interactions (PPI) between TRAF proteins and their upstream receptors or downstream effectors, and inhibition of the RING domain-mediated E3 ubiquitin ligase activity to prevent downstream signaling cascades like NF-kappaB (PubMed: 29351476).